TherapeuticsMD Inc (NASDAQ:TXMD) – Stock analysts at Oppenheimer lowered their FY2020 earnings estimates for TherapeuticsMD in a report issued on Wednesday. Oppenheimer analyst J. Olson now anticipates that the company will earn $0.27 per share for the year, down from their prior forecast of $0.33. Oppenheimer currently has a “Buy” rating and a $10.00 price objective on the stock. Oppenheimer also issued estimates for TherapeuticsMD’s FY2021 earnings at $0.45 EPS.
TherapeuticsMD (NASDAQ:TXMD) last released its earnings results on Tuesday, February 20th. The company reported ($0.10) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.01). TherapeuticsMD had a negative net margin of 458.49% and a negative return on equity of 65.30%. The company had revenue of $4.13 million for the quarter, compared to the consensus estimate of $4.66 million. During the same period in the prior year, the company earned ($0.12) earnings per share. The firm’s revenue was down 8.0% on a year-over-year basis.
A number of other research firms also recently weighed in on TXMD. Cantor Fitzgerald reissued a “buy” rating and set a $28.00 target price on shares of TherapeuticsMD in a research report on Sunday, January 7th. BidaskClub raised shares of TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research report on Tuesday, December 12th. Cowen reissued an “outperform” rating and set a $16.00 target price (up from $13.00) on shares of TherapeuticsMD in a research report on Monday, November 6th. Zacks Investment Research raised shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research report on Saturday, January 20th. Finally, Noble Financial reissued a “buy” rating on shares of TherapeuticsMD in a research report on Thursday, November 30th. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company’s stock. TherapeuticsMD has an average rating of “Buy” and a consensus target price of $14.50.
TherapeuticsMD (TXMD) traded down $0.10 during trading on Friday, hitting $5.01. 3,035,500 shares of the stock were exchanged, compared to its average volume of 1,852,551. TherapeuticsMD has a 1 year low of $3.50 and a 1 year high of $8.30. The company has a market cap of $1,160.00, a P/E ratio of -14.51 and a beta of 0.99.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in TXMD. TIAA CREF Investment Management LLC boosted its holdings in TherapeuticsMD by 7.7% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 421,181 shares of the company’s stock worth $2,220,000 after buying an additional 30,183 shares during the period. Northern Trust Corp boosted its holdings in TherapeuticsMD by 10.3% in the 2nd quarter. Northern Trust Corp now owns 2,060,175 shares of the company’s stock worth $10,858,000 after buying an additional 192,079 shares during the period. Vanguard Group Inc. boosted its holdings in TherapeuticsMD by 4.4% in the 2nd quarter. Vanguard Group Inc. now owns 10,231,081 shares of the company’s stock worth $53,918,000 after buying an additional 429,211 shares during the period. Virtu KCG Holdings LLC bought a new position in TherapeuticsMD in the 2nd quarter worth approximately $157,000. Finally, State Street Corp boosted its holdings in TherapeuticsMD by 14.9% in the 2nd quarter. State Street Corp now owns 4,486,585 shares of the company’s stock worth $23,647,000 after buying an additional 583,094 shares during the period. 71.40% of the stock is owned by institutional investors.
In other TherapeuticsMD news, Director Tommy G. Thompson acquired 5,000 shares of the business’s stock in a transaction that occurred on Friday, December 8th. The stock was bought at an average cost of $6.21 per share, with a total value of $31,050.00. Following the acquisition, the director now owns 3,555 shares in the company, valued at $22,076.55. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 23.92% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: “FY2020 EPS Estimates for TherapeuticsMD Inc Reduced by Analyst (TXMD)” was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://transcriptdaily.com/2018/02/23/fy2020-eps-estimates-for-therapeuticsmd-inc-reduced-by-analyst-txmd.html.
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.